The traditionally deliberative FDA apparently thinks a cryotherapy system developed by CryoCath Technologies (Kirkland, Quebec), which uses extremely cold temperatures to treat diseased tissue, is a hot commodity, granting the product an approval about five months ahead of schedule, an almost unheard-of feat for the agency.